Three novel beta-galactosidase gene mutations in Han Chinese patients with GM1 gangliosidosis are correlated with disease severity
© Yang et al; licensee BioMed Central Ltd. 2010
Received: 5 May 2010
Accepted: 30 September 2010
Published: 30 September 2010
GM1 gangliosidosis (GM1) is an autosomal recessive lysosomal storage disease caused by deficiency of acid beta-galactosidase (GLB1; EC188.8.131.52). Here, we identify three novel mutations in the GLB1 gene from two Han Chinese patients with GM1 that appear correlated with clinical phenotype.
One of the two Han Chinese patients with GM1 presented with the juvenile form, and the other with the infantile form with cardiac involvement. Sequencing of the entire GLB1 gene revealed three novel mutations (p.H102 D, p.G494V, c.495_497delTCT), which were absent in 94 normal controls. Transient expression of cDNA encoding these variants was performed in COS-1 cells to evaluate β-galactosidase activities.
The first case (patient 1) with the juvenile form contained two missense mutations, p.H102 D and p.A301V. Patient 2 diagnosed with the infantile form of the disease with cardiac involvement was compound heterozygous for p.G494V and c.495_497delTCT mutations. All mutant beta-galactosidases exhibited significantly reduced activity (12%, 0%, 0%, and 0% for p.H102 D, p.A301V, p.G494V, and c.495_497delTCT), compared with the wild-type beta-galactosidase cDNA clone. The mutations identified in patient 2 with cardiomyopathy were localized in the GLB1 gene region common to both lysosomal beta-galactosidase and elastin binding protein (EBP), and caused a deletion in the elastin-binding domain of EBP.
All four mutations identified in Han Chinese patients induce significant suppression of β-galactosidase activity, correlating with severity of disease and presence of cardiomyopathy.
Human β-galactosidase (E.C.184.108.40.206; MIM# 230500) is an lysosomal enzyme that removes β-ketosidically linked galactose residues from glycoproteins, sphingolipids, and keratin sulfate . Deficiency of acid β-galactosidase leads to two metabolic storage diseases, specifically, GM1 gangliosidosis (GM1) and Morquio B disease (MBD, mucopolysaccharidosis type IVB, MPS IVB), inherited as autosomal recessive traits. In GM1 gangliosidosis, absence or suppression of β-galactosidase activity causes excessive accumulation of GM1 ganglioside in neuronal tissue while β-linked galactose-terminal oligosaccharides arising from the lysosomal digestion of glycoproteins are stored in visceral organs and excreted in urine. Three major clinical phenotypes have been classified to date: infantile (type I), late infantile/juvenile (type II), and adult (type III) forms . The most severe infantile form with onset between birth and 6 months results in rapidly progressive central nervous system (CNS) degeneration, visceromegaly, cherry-red spots, skeletal abnormalities, and death usually occurring within the first two years of life. Cardiomyopathy is an atypical clinical feature in some Caucasian patients with infantile GM1 gangliosidosis. The residual β-galactosidase activity in fibroblasts from patients is less than 1.3%, compared to the physiological level. However, the juvenile and adult forms of GM1 gangliosidosis display a less severe course, later age of onset, and higher β-galactosidase activity, varying from 0.3 to 4.8% of the normal level in the juvenile form and ~9% in the adult form [1, 2].
In contrast to GM1 gangliosidosis, Morquio B disease (MBD) is characterized by severe skeletal dysplasia without CNS involvement. MBD is also associated with deficiency of acid β-galactosidase, but the metabolic storage substance in this case is keratin sulfate, a glycosaminoglycan accumulating in the cornea and skeletal tissue and secreted in urine, and not GM1 ganglioside in the brain .
The human β-galactosidase gene (GLB1) located on chromosome 3p21.33  contains 16 exons spanning approximately 62.5 kb [3, 4]. The GLB1 gene encodes two alternatively spliced products, lysosomal β-galactosidase (GLB1) and elastin-binding protein (EBP) [5–7]. The GLB1 protein is synthesized as an N-glycosylated 85 kDa precursor, and processed within lysosomes to a 64 kDa mature enzyme [8–10]. The active enzyme forms complexes with the 54 kDa protective protein/cathepsin A (PPCA) and the 46 kDa neuraminidase (NEU1) in lysosomes. PPCA is essential for intracellular transport and intralysosomal activity/stabilization of both β-galactosidase and NEU1 [11, 12]. NEU1 catalyzes hydrolysis of the terminal sialic acids of oligosaccharides, glycoproteins and glycolipids [13, 14]. The alternative splice product, EBP, results from deletion of exons 3, 4 and 6, and a frameshift in the translation of exon 5 encoding the unique elastin binding domain of EBP [5, 15].
Cardiomyopathy in GM1 gangliosidosis is associated with impaired elastogenesis and EBP defects [16–19]. EBP, a 67 kDa enzymatically inactive variant of β-galactosidase, is not targeted to lysosomes. Earlier studies show that EBP acts as a recycling chaperone that protects tropoelastin from premature degradation and delivers it through an intracellular secretory pathway to the cell surface where tropoelastin is secreted into the extracellular matrix and assembled [6, 20–22]. Tropoelastin is released from EBP following a conformational change that occurs after the galactolectin domain of EBP binds to galatosugars protruding from glycoproteins on the microfibrillar scaffold of growing elastic fibers [6, 21]. Following tropoelastin release, EBP returns to the endosomes, binds to newly synthesized tropoelastin in the trans-Golgi network, and delivers it to the cell surface . EBP additionally forms complexes with PPCA and NEU1 to facilitate elastic fiber assembly on the cell surface . PPCA appears to act as a protective protein, while NEU1 is required for the release of tropoelastin and the signaling pathway induced by the complex [25, 26].
To date, More than 130 mutations have been identified in the GLB1 gene [2, 27, 28]. In this study, we investigate the GLB1 mutations associated with GM1 gangliosidosis in two Han Chinese patients. Three of the mutations identified in these two patients were novel and have not been reported in patients of other ethnicities. We further evaluate the contribution of individual mutations to the clinical phenotype via site-directed mutagenesis experiments, examination of expression levels in COS-1 cells, and β-galactosidase activity measurements. One of the patients (patient 2) with cardiac involvement presented two mutations likely to affect both lysosomal GLB1 and EBP proteins, including a deletion in the elastin-binding domain of EBP. Our findings suggest a correlation between these mutations and the presence of cardiomyopathy.
Patients and Methods
Clinical and molecular features of two Taiwanese patients with GM1 gangliosidosis
Age of onset
Age at diagnosis
Developmental regression, delayed psychomotor development, coarse facial features, macroglossia, abdominal distention, and thick skin with Mongolian spots
Developmental regression, hypotonia, bilateral hydrocele, and visceromegaly
Cherry red spot
Dilated cardiomyopathy, Hypertrophied left atrium/ventricle, and poor contractility of left ventricle
Scoliosis and beaking of the lumbar vertebral bodies
White matter demyelination and cortical atropy
White matter demyelination, cortical atropy, and seizure
Foamy histiocytes and progressive leukomalacia
Age of death
2 years, 2 months
2% of control value in fibroblast
< 1% of control value in fibroblast
c.304C > G (p.H102 D, inherited from father)
c.495_497delTCT (p.L166del, inherited from mother)
c.902C > T (p.A301V, inherited from mother)
c.1481G > T (p.G494V, inherited from father)
Patient 2 presented with the infantile form of the disease, and was the first child of a healthy non-consanguineous couple with no contributory family history. He had developmental retardation, and visceromegaly developed soon after birth. At 3 months of age, the patient presented with macular cherry-red spots and hepatomegaly. Hypotonia and bilateral hydrocele were noted at 4 months of age. The roentgenogram and echocardiogram findings included cardiomegaly, dilated cardiomyopathy, hypertrophied left atrium/ventricle, and poor contractility of the left ventricle. Residual β-galactosidase activity was lower than 1% of the normal level. MR imaging at 3, 12 and 23 months revealed significant myelination arrest with dysmyelination of white matter in the bilateral cerebral hemispheres and atropic change of the brain cortex . The patient died of congestive heart failure and seizure at 2 years of age.
Healthy controls were randomly selected from the Taiwan Han Chinese Cell and Genome Bank . All participating patients and controls were Han Chinese, which is the origin of 98% of the Taiwanese population. The study was approved by the institutional review board and the ethics committee of each institution. Written informed consent was obtained from participants, in accordance with institutional requirements and the Declaration of Helsinki Principles.
Genomic DNA was isolated from peripheral blood or fibroblasts using standard techniques. We sequenced all exons of the β-galactosidase gene (GLB1), including the 5' and 3' untranslated regions and intron/exon boundaries. PCR primers were designed using the Primer 3 program http://frodo.wi.mit.edu/cgi-bin/primer3/primer3_www.cgi. Amplified products from genomic DNA were purified from the agarose gel using QIAEX II (Qiagen, Hilden, Germany), and directly sequenced in both directions using a BigDye Terminator cycle sequencing kit with an ABI Prism 377 DNA Sequencer (Applied Biosystems, Foster City, CA). The GLB1 genomic sequence was derived from GenBank, NT_022517.16. Nucleotide numbering was based on the cDNA reference sequence from GenBank, NM_000404.2, according to the journal guidelines http://www.hgvs.org/mutnomen, with A of the ATG start codon as +1.
Construction of the GLB1 expression plasmid, pGS3
Total RNA was extracted from a normal lymphocyte cell line, and cDNA synthesized using the Advantage RT-for-PCR kit (Clontech, Palo Alto, CA) with an oligo-dT primer. Amplification of wild-type GLB1 gene was performed with the following oligonucleotides: forward, 5'-GTCATGCCGGGGTTCCTGGTTC-3', and reverse, 5'-GTCCCTGAAGGTGGGGCTTTGG-3', using the Expand™ High Fidelity PCR system (Boehringer Mannheim, Indianapolis, IN). The 2.21 kb PCR product was ligated into the TOPO TA cloning kit vector (Invitrogen, Carlsbad, CA), and the nucleotide sequence and orientation of the insert in the resulting plasmid, pTA-GS, verified by direct sequencing. The Hin dIII-Xba I fragment of pTA-GS was further subcloned into the expression vector, pcDNA3.1 (Invitrogen, Carlsbad, CA), generating the GLB1 expression plasmid, pGS3.
Construction of mutant β-galactosidase expression plasmids with deletion and missense mutations
Primers used for site-directed mutagenesis
Amino acid change
Oligonucleotides (5' -> 3')
c.304C > G
R: CCTGGCCAGGACAGTACCAGTTTTCTGAGGACG ATGATGTGGAATATTTTC
c.902C > T
F: AAGTATATCATAGAGGGAGGAAGCCACT GCTTCGGTCTTG
c.1481G > T
R: GAACTATGGTGCATATATCAACGATTTTAAGGT TTTGGTTTCTAACCTG
Transient transfection of COS-1 cells
COS-1 cells were cultured in DMEM and 10% fetal bovine serum supplemented with 100 U/ml penicillin, 100 μg/ml streptomycin and 2 mM L-glutamine. Cells were grown to 85-90% confluency in each well of a 6-well plate, and separately transfected with 4 μg of pGS3-H102 D, pGS3-c.495_497delTCT, pGS3-A301V, pGS3-G494V and wild-type pGS3. Transfection was performed using the Lipofectamine™ 2000 reagent (Gibco BRL, Grand Island, NY), according to the manufacturer's instructions. After 48 h incubation at 37°C, cells were scraped and washed twice with PBS. Cell pellets were frozen at -70°C until use for protein content determination and assay of enzyme activity.
Transfected cells were resuspended in distilled water, and subjected to sonication using a Misonix Ultrasonic processor (XL2020) at a power level of 10 for 15 s in ice. Soluble lysates were collected and protein concentrations determined using the Bio-Rad assay kit (Hercules, CA) with bovine serum albumin as a standard. The GLB1 enzyme assay was performed using the artificial substrate, 4-methylumbelliferyl-β-D-galactopyranoside (Sigma, St. Louis, MO) [32, 33]. Briefly, β-galactosidase activity was measured in duplicate by adding 100 μl of enzyme solution to 300 μl of 0.65 mM substrate solution (4-methylumbelliferyl-β-D-galactopyranoside in 0.1 M citrate-phosphate buffer, pH 4.2). After incubation at 37°C for 1 h, all reactions were terminated by adding 1 ml of 0.1 M 2-methylpropan-1-ol, pH 10. Fluorescence was determined with a PerSeptive Biosystems (Cytofluor® series 4000) fluorescence multi-well plate reader (Applied Biosystems, Foster City, CA). A known amount of 4-methylumbelliferone (Sigma, St. Louis, MO) in 0.1 M 2-methylpropan-1-ol, pH 10, was employed as the standard.
Molecular analysis of GM1-gangliosidosis patients
Transient expression of GLB1 plasmids in COS-1 cells
β-Galactosidase activity measured in transiently transfected COS-1 cell lysates
Specific Activity (nmol/hr/mg of protein)1
Percentage of wild-type activity2
320 ± 21.1
534 ± 27.7
346 ± 19.4
237 ± 14.5
260 ± 20.3
294 ± 27.5
More than 130 mutations in the GLB1 gene have been reported in GM1 or MBD cases from Japan, Northern/Southern America, and Europe. The majority of mutations appear to cluster in exons 2, 6, and 15 of the GLB1 gene . These "hotspot" regions play important catalytic and/or regulatory roles. Here, we perform mutational analysis of two Han Chinese patients with GM1. Clinical manifestations of the patients can be distinguished according to the presence or absence of cardiac involvement. This atypical clinical feature has been reported in limited Caucasian patients. Three mutations in the GLB1 gene identified from the entire pathogenic allele of these two patients have not been reported previously. The variable severity of these clinical manifestations correlates with the mutation combinations. Patient 1, diagnosed with juvenile GM1 gangliosidosis without cardiomyopathy, is compound heterozygous for p.H102 D in exon 3 and p.A301V in exon 8, respectively. Although substitution of valine at position 301 with alanine seems to be homologous and non-deleterious, COS-1 cells expressing cDNA encoding p.A301V in vitro displayed no GLB1 enzyme activity. Low enzyme activity (~12% of the physiological level) was detected in COS-1 cells transfected with cDNA encoding the p.H102 D substitution. The p.H102 D appears to be a mild mutation responsible for the less severe phenotype of our juvenile patient displaying 2% residual enzyme activity. The p.A301V has been found in our patient 1 and in another juvenile patient , both presenting juvenile GM1 with central nervous system involvement and skeletal affection as well as absence of cardiac dysfunction and cherry red spots. The p.H102 D alone or combined with p.A301V can be related to hepatosplenomegaly.
Both c.495_497delTCT and p.G494V mutations identified in patient 2 led to absence of GLB1 enzyme activity in transient expression studies, correlating with lack of in vivo residual enzyme activity (< 1%). Two transcripts are processed from the primary β-galactosidase transcript, specifically, the classical lysosomal form of 677 amino acid β-galactosidase (GLB1) and the elastin binding protein (EBP) containing 546 residues in which exons 3, 4, and 6 are spliced out from pre-mRNA and exon 5 is frameshifted . The frameshift in exon 5 results in a unique form of EBP, a 32-residue sequence containing an elastin/laminin-binding domain . The two heterozygous mutations identified in patient 2 displaying cardiac involvement are localized in the GLB1 gene region common to the two transcripts, and thus affects both the lysosomal GLB1 enzyme and EBP protein. Both mutations can be related to infantile GM1 with cardiac dysfunction, as well as central nervous system involvement, cherry red spots and lack of skeletal affection.
The c.495_497delTCT mutation of the GLB1 transcript corresponds to a c.283_285delTCT variation of the EBP transcript, leading to in-frame deletion of an amino acid, p.Ser95del, in the elastin/laminin-binding domain of EBP. This variation in the elastin-binding domain of the EBP protein may directly impair tropoelastin binding to EBP and assembly of elastic fibers, which are consequently linked to the patient's cardiac involvement. Our data additionally support an association of EBP with cardiac involvement in GM1 gangliosidosis [16–19].
We identified three novel genetic mutations in the GLB1 coding region from Chinese patients with GM1. Patient 1 presented with the juvenile form of GM1 and 2% residual β-galactosidase activity in cultured fibroblasts. Expression of the two GLB1 mutants identified in patient 1, p.H102 D and p.A301V, in COS-1 cells led to 12% and 0% of normal activity. Patient 2 presented with the infantile form of GM1 and less than 1% of residual β-galactosidase activity in cultured fibroblasts. The two mutants, p.G949V and c.934-7del (p.L166del), identified from patient 2 were devoid of activity upon expression in COS-1 cells. The two mutations in patient 2 were localized in the GLB1 gene region common to lysosomal GLB1 and EBP, and could therefore affect both proteins. All the mutations correlated with the clinical manifestations of patients and residual β-galactosidase activity in cultured fibroblasts. While elastic fiber deposition requires further evaluation in patients, it is plausible that impaired elastogenesis and cardiomyopathy in GM1 gangliosidosis are caused by defects in the elastin-binding domain of EBP.
elastin binding protein
protective protein/cathepsin A
The authors are grateful to the patients and their parents for their participation in the study. This work was supported by China Medical University Hospital (grant number: DMR-92-079), Taichung, Taiwan and the National Science Council (grant number: NSC 89-2314-B-039-003), Taipei, Taiwan.
- Suzuki Y, Oshima A, Namba E: GM1-gangliosidosis and Morquio B disease. 2001, New York: McGraw-Hill, 8Google Scholar
- Brunetti-Pierri N, Scaglia F: GM1 gangliosidosis: review of clinical, molecular, and therapeutic aspects. Mol Genet Metab. 2008, 94: 391-396. 10.1016/j.ymgme.2008.04.012.View ArticlePubMedGoogle Scholar
- Yamamoto Y, Hake CA, Martin BM, Kretz KA, Ahern-Rindell AJ, Naylor SL, Mudd M, O'Brien JS: Isolation, characterization, and mapping of a human acid beta-galactosidase cDNA. DNA Cell Biol. 1990, 9: 119-127. 10.1089/dna.1990.9.119.View ArticlePubMedGoogle Scholar
- Morreau H, Bonten E, Zhou XY, D'Azzo A: Organization of the gene encoding human lysosomal beta-galactosidase. DNA Cell Biol. 1991, 10: 495-504. 10.1089/dna.1991.10.495.View ArticlePubMedGoogle Scholar
- Morreau H, Galjart NJ, Gillemans N, Willemsen R, van der Horst GT, d'Azzo A: Alternative splicing of beta-galactosidase mRNA generates the classic lysosomal enzyme and a beta-galactosidase-related protein. J Biol Chem. 1989, 264: 20655-20663.PubMedGoogle Scholar
- Hinek A: Biological roles of the non-integrin elastin/laminin receptor. Biol Chem. 1996, 377: 471-480.PubMedGoogle Scholar
- Privitera S, Prody CA, Callahan JW, Hinek A: The 67-kDa enzymatically inactive alternatively spliced variant of beta-galactosidase is identical to the elastin/laminin-binding protein. J Biol Chem. 1998, 273: 6319-6326. 10.1074/jbc.273.11.6319.View ArticlePubMedGoogle Scholar
- D'Azzo A, Hoogeveen A, Reuser AJ, Robinson D, Galjaard H: Molecular defect in combined beta-galactosidase and neuraminidase deficiency in man. Proc Natl Acad Sci USA. 1982, 79: 4535-4539. 10.1073/pnas.79.15.4535.PubMed CentralView ArticlePubMedGoogle Scholar
- Nanba E, Tsuji A, Omura K, Suzuki Y: GM1-gangliosidosis: abnormalities in biosynthesis and early processing of beta-galactosidase in fibroblasts. Biochem Biophys Res Commun. 1988, 152: 794-800. 10.1016/S0006-291X(88)80108-6.View ArticlePubMedGoogle Scholar
- van der Spoel A, Bonten E, d'Azzo A: Processing of lysosomal beta-galactosidase. The C-terminal precursor fragment is an essential domain of the mature enzyme. J Biol Chem. 2000, 275: 10035-10040. 10.1074/jbc.275.14.10035.View ArticlePubMedGoogle Scholar
- Morreau H, Galjart NJ, Willemsen R, Gillemans N, Zhou XY, d'Azzo A: Human lysosomal protective protein. Glycosylation, intracellular transport, and association with beta-galactosidase in the endoplasmic reticulum. J Biol Chem. 1992, 267: 17949-17956.PubMedGoogle Scholar
- Bonten E, van der Spoel A, Fornerod M, Grosveld G, d'Azzo A: Characterization of human lysosomal neuraminidase defines the molecular basis of the metabolic storage disorder sialidosis. Genes Dev. 1996, 10: 3156-3169. 10.1101/gad.10.24.3156.View ArticlePubMedGoogle Scholar
- Achyuthan KE, Achyuthan AM: Comparative enzymology, biochemistry and pathophysiology of human exo-alpha-sialidases (neuraminidases). Comp Biochem Physiol B Biochem Mol Biol. 2001, 129: 29-64. 10.1016/S1096-4959(01)00372-4.View ArticlePubMedGoogle Scholar
- Seyrantepe V, Poupetova H, Froissart R, Zabot MT, Maire I, Pshezhetsky AV: Molecular pathology of NEU1 gene in sialidosis. Hum Mutat. 2003, 22: 343-352. 10.1002/humu.10268.View ArticlePubMedGoogle Scholar
- Hinek A, Rabinovitch M, Keeley F, Okamura-Oho Y, Callahan J: The 67-kD elastin/laminin-binding protein is related to an enzymatically inactive, alternatively spliced form of beta-galactosidase. J Clin Invest. 1993, 91: 1198-1205. 10.1172/JCI116280.PubMed CentralView ArticlePubMedGoogle Scholar
- Morrone A, Bardelli T, Donati MA, Giorgi M, Di Rocco M, Gatti R, Parini R, Ricci R, Taddeucci G, D'Azzo A, Zammarchi E: beta-galactosidase gene mutations affecting the lysosomal enzyme and the elastin-binding protein in GM1-gangliosidosis patients with cardiac involvement. Hum Mutat. 2000, 15: 354-366. 10.1002/(SICI)1098-1004(200004)15:4<354::AID-HUMU8>3.0.CO;2-L.View ArticlePubMedGoogle Scholar
- Hinek A, Wilson SE: Impaired elastogenesis in Hurler disease: dermatan sulfate accumulation linked to deficiency in elastin-binding protein and elastic fiber assembly. Am J Pathol. 2000, 156: 925-938.PubMed CentralView ArticlePubMedGoogle Scholar
- Caciotti A, Donati MA, Boneh A, d'Azzo A, Federico A, Parini R, Antuzzi D, Bardelli T, Nosi D, Kimonis V: Role of beta-galactosidase and elastin binding protein in lysosomal and nonlysosomal complexes of patients with GM1-gangliosidosis. Hum Mutat. 2005, 25: 285-292. 10.1002/humu.20147.View ArticlePubMedGoogle Scholar
- Caciotti A, Donati MA, Bardelli T, d'Azzo A, Massai G, Luciani L, Zammarchi E, Morrone A: Primary and secondary elastin-binding protein defect leads to impaired elastogenesis in fibroblasts from GM1-gangliosidosis patients. Am J Pathol. 2005, 167: 1689-1698.PubMed CentralView ArticlePubMedGoogle Scholar
- Hinek A, Rabinovitch M: 67-kD elastin-binding protein is a protective "companion" of extracellular insoluble elastin and intracellular tropoelastin. J Cell Biol. 1994, 126: 563-574. 10.1083/jcb.126.2.563.View ArticlePubMedGoogle Scholar
- Hinek A: Nature and the multiple functions of the 67-kD elastin-/laminin binding protein. Cell Adhes Commun. 1994, 2: 185-193. 10.3109/15419069409004436.View ArticlePubMedGoogle Scholar
- Hinek A, Wrenn DS, Mecham RP, Barondes SH: The elastin receptor: a galactoside-binding protein. Science. 1988, 239: 1539-1541. 10.1126/science.2832941.View ArticlePubMedGoogle Scholar
- Hinek A, Keeley FW, Callahan J: Recycling of the 67-kDa elastin binding protein in arterial myocytes is imperative for secretion of tropoelastin. Exp Cell Res. 1995, 220: 312-324. 10.1006/excr.1995.1321.View ArticlePubMedGoogle Scholar
- Pshezhetsky AV, Ashmarina M: Lysosomal multienzyme complex: biochemistry, genetics, and molecular pathophysiology. Prog Nucleic Acid Res Mol Biol. 2001, 69: 81-114. full_text.View ArticlePubMedGoogle Scholar
- Hinek A, Pshezhetsky AV, von Itzstein M, Starcher B: Lysosomal sialidase (neuraminidase-1) is targeted to the cell surface in a multiprotein complex that facilitates elastic fiber assembly. J Biol Chem. 2006, 281: 3698-3710. 10.1074/jbc.M508736200.View ArticlePubMedGoogle Scholar
- Duca L, Blanchevoye C, Cantarelli B, Ghoneim C, Dedieu S, Delacoux F, Hornebeck W, Hinek A, Martiny L, Debelle L: The elastin receptor complex transduces signals through the catalytic activity of its Neu-1 subunit. J Biol Chem. 2007, 282: 12484-12491. 10.1074/jbc.M609505200.View ArticlePubMedGoogle Scholar
- Hofer D, Paul K, Fantur K, Beck M, Burger F, Caillaud C, Fumic K, Ledvinova J, Lugowska A, Michelakakis H: GM1 gangliosidosis and Morquio B disease: expression analysis of missense mutations affecting the catalytic site of acid beta-galactosidase. Hum Mutat. 2009, 30: 1214-1221. 10.1002/humu.21031.View ArticlePubMedGoogle Scholar
- Hofer D, Paul K, Fantur K, Beck M, Roubergue A, Vellodi A, Poorthuis B, Michelakakis H, Plecko B, Paschke E: Phenotype determining alleles in GM1 gangliosidosis patients bearing novel GLB1 mutations. Clin Genet. 2010, 78 (3): 236-246. 10.1111/j.1399-0004.2010.01379.x.View ArticlePubMedGoogle Scholar
- Lin HC, Tsai FJ, Shen WC, Tsai CH, Peng CT: Infantile form GM1 gangliosidosis with dilated cardiomyopathy: a case report. Acta Paediatr. 2000, 89: 880-883. 10.1080/080352500750043828.View ArticlePubMedGoogle Scholar
- Pan WH, Fann CS, Wu JY, Hung YT, Ho MS, Tai TH, Chen YJ, Liao CJ, Yang ML, Cheng AT, Chen YT: Han Chinese cell and genome bank in Taiwan: purpose, design and ethical considerations. Hum Hered. 2006, 61: 27-30. 10.1159/000091834.View ArticlePubMedGoogle Scholar
- Ansaldi M, Lepelletier M, Mejean V: Site-specific mutagenesis by using an accurate recombinant polymerase chain reaction method. Anal Biochem. 1996, 234: 110-111. 10.1006/abio.1996.0060.View ArticlePubMedGoogle Scholar
- Zhang S, Bagshaw R, Hilson W, Oho Y, Hinek A, Clarke JT, Callahan JW: Characterization of beta-galactosidase mutations Asp332-- > Asn and Arg148-- > Ser, and a polymorphism, Ser532-- > Gly, in a case of GM1 gangliosidosis. Biochem J. 2000, 348 (Pt 3): 621-632. 10.1042/0264-6021:3480621.PubMed CentralView ArticlePubMedGoogle Scholar
- Hubbes M, D'Agrosa RM, Callahan JW: Human placental beta-galactosidase. Characterization of the dimer and complex forms of the enzyme. Biochem J. 1992, 285 (Pt 3): 827-831.PubMed CentralView ArticlePubMedGoogle Scholar
This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.